Investor Relations
Corporate Profile
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based, vertically integrated medical technology company focused on developing and commercializing novel technologies for weight loss. Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
IR Kit
Fourth Quarter 2016 Press Release
424B Filing

Stock Quote
OBLN (Common Stock) $10.21  - 0.06 (0.00%)
ExchangeNASDAQ
Volume36,131
Today's Open$10.20
Previous Close$10.21
Data as of 03/23/17 4:00 p.m. ET    Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.


Stock Chart
Stock chart for: OBLN.O.  Currently trading at $10.21 with a 52 week high of $15.88 and a 52 week low of $8.27.

Upcoming Events
There are currently no events scheduled.

IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click on Safety Information and Patient Labeling